Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
企業コードLEGN
会社名Legend Biotech Corp
上場日Jun 04, 2020
設立日2015
最高経営責任者「CEO」Dr. Ying Huang, Ph.D.
従業員数2600
証券種類Depository Receipt
決算期末Jun 04
本社所在地2101 Cottontail Lane
都市SOMERSET
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号08873
電話番号17328505598
ウェブサイトhttps://investors.legendbiotech.com/
企業コードLEGN
上場日Jun 04, 2020
設立日2015
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし